Related Experiment Video
Updated: Jan 15, 2026

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Currently managed US prevalence of cutaneous venous malformations (cVMs): a nationally representative, retrospective,
Jack Ray Gallagher1, Susan Carroll2, Jeffrey Martini3
1Clarity Pharma Research, LLC, 511 Audubon, Spartanburg, SC, 29302, USA.
Insights
Cutaneous venous malformations (cVMs) affect nearly 200,000 individuals annually in the U.S. This study highlights the need for better treatments and care access for this rare vascular condition.
Area of Science:
- Vascular Anomalies
- Epidemiology
- Dermatology
Background:
- Cutaneous venous malformations (cVMs) are rare vascular anomalies causing disfigurement and pain.
- Limited treatment options exist due to poor drug penetration and lack of FDA-approved therapies.
- Epidemiologic data on cVMs is scarce, necessitating real-world studies.
Purpose of the Study:
- To estimate the annual treatment prevalence of cVMs in the United States.
- To provide crucial epidemiologic data for this understudied condition.
- To inform future research and therapeutic development for cVMs.
Main Methods:
- A nationally representative, blinded, observational probability study was conducted.
- Physicians from various specialties were recruited via blinded invitations.
- Participants self-reported treated cVM patients, with estimates adjusted for comanagement.
Main Results:
- 515 physicians completed the survey, with 376 managing cVM patients.
- The estimated annual prevalence was 194,195 patients (0.06% of the U.S. population).
- This includes 135,687 with cutaneous-only and 58,508 with mixed lesions.
Conclusions:
- cVMs affect a substantial number of individuals across all age groups in the U.S.
- Findings emphasize the need for improved access to care for cVM patients.
- Development of targeted therapies is crucial for this debilitating condition.
Background:
Cutaneous venous malformations (cVMs) are rare vascular anomalies characterized by progressive vessel ectasia, leading to disfigurement, pain, ulceration, and bleeding. These lesions often evade early detection and are notoriously difficult to treat due to the limited dermal bioavailability of systemic therapies. Unlike deep venous malformations, cVMs present unique management challenges and currently lack FDA-approved treatments. To address the paucity of epidemiologic data, we conducted a nationally representative, blinded, real-world observational probability study to estimate the annual treatment prevalence of cVM in the United States. A geographically representative sample of dermatologists, hematologist-oncologists, pediatricians, radiologists, and vascular surgeons was recruited via blinded invitations. Participants self-reported the number of cVM patients treated in the prior 12 months. Estimates were adjusted for comanagement to calculate the national prevalence of unique patients.
Results:
Of 691 physicians who accessed the study website, 515 (74.5%) completed the survey; 376 (73.0%) reported managing at least one patient with cutaneous-only or mixed (cutaneous and internal) VMs. The estimated annual prevalence was 194,195 patients (95% CI 188,852-200,228), including 135,687 with cutaneous-only VMs and 58,508 with mixed lesions. This corresponds to a prevalence of 0.06% (US population).
Conclusions:
While cVM is rare, it affects a substantial number of individuals across age groups in the U.S. These findings underscore the need for improved access to care and the development of targeted therapies for this understudied, debilitating condition.
More Related Videos
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Varicose Veins I: Introduction
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

